广东恒健制药有限公司

Language

It is suggested that the hierarchical management of drugs should be carried out to prevent the expired patent drugs from becoming aristocrats

Date:2020-03-03

"When the medical system reform plan is introduced, it will inevitably bring a new round of reshuffle to China's pharmaceutical industry. Now our company has stopped all new drug research and development work, waiting for the introduction of the medical reform plan. Because now the development of pharmaceutical companies has reached the most confused moment. " The general manager of a pharmaceutical company couldn't conceal his emotion when he spoke.


Yesterday, at the Symposium on "medical system reform and medical industry development" sponsored by Beijing Pharmaceutical Industry Association, the leaders of 10 famous pharmaceutical enterprises in Beijing rarely appeared together, but the only reason is that they are now facing a survival crisis together.


The high price of the original research drug has no rules to follow


"At present, the annual profit of pharmaceutical enterprises is only about 5%, but the R & D investment of a class II or above new drug is between tens of millions and hundreds of millions, which can be completed in more than 10 years. But in the case of reducing drug prices for many times, the profits of Chinese pharmaceutical enterprises have decreased year by year, so it is almost impossible to develop patent drugs. " Yesterday, a senior manager of the participating enterprises said.


However, under the circumstances that the survival of Chinese pharmaceutical enterprises is very difficult, a kind of drug called original research drug enjoys the preferential policy of high pricing, and what's more puzzling is that more than 10 executives from pharmaceutical enterprises have expressed their incomprehension about why the original research drug can be set at a high price.


According to reports, now, the price of the original research drugs may be twice or even several times higher than that of the generic drugs of the same variety, but the so-called original research drugs mainly refer to the expired patent drugs of some multinational pharmaceutical enterprises. "Since the patent has expired, we should compete fairly with other generic drugs in the market. Now, China's high pricing of original research drugs not only damages the fragile profits of China's pharmaceutical industry, but also is not conducive to reducing drug prices. Because with the competition of generic drugs, we can reduce the price of the original research drugs, and at the same time, we can also make multinational pharmaceutical companies launch new drugs to China faster. " The president of the pharmaceutical company stressed repeatedly.


"When the medical system reform plan is introduced, it will inevitably bring a new round of reshuffle to China's pharmaceutical industry. Now our company has stopped all new drug research and development work, waiting for the introduction of the medical reform plan. Because now the development of pharmaceutical companies has reached the most confused moment. " The general manager of a pharmaceutical company couldn't conceal his emotion when he spoke.


Yesterday, at the Symposium on "medical system reform and medical industry development" sponsored by Beijing Pharmaceutical Industry Association, the leaders of 10 famous pharmaceutical enterprises in Beijing rarely appeared together, but the only reason is that they are now facing a survival crisis together.


The high price of the original research drug has no rules to follow


"At present, the annual profit of pharmaceutical enterprises is only about 5%, but the R & D investment of a class II or above new drug is between tens of millions and hundreds of millions, which can be completed in more than 10 years. But in the case of reducing drug prices for many times, the profits of Chinese pharmaceutical enterprises have decreased year by year, so it is almost impossible to develop patent drugs. " Yesterday, a senior manager of the participating enterprises said.


However, under the circumstances that the survival of Chinese pharmaceutical enterprises is very difficult, a kind of drug called original research drug enjoys the preferential policy of high pricing, and what's more puzzling is that more than 10 executives from pharmaceutical enterprises have expressed their incomprehension about why the original research drug can be set at a high price.


According to reports, now, the price of the original research drugs may be twice or even several times higher than that of the generic drugs of the same variety, but the so-called original research drugs mainly refer to the expired patent drugs of some multinational pharmaceutical enterprises. "Since the patent has expired, we should compete fairly with other generic drugs in the market. At present, China 's high pricing of original research drugs not only damages China' s fragile pharmaceutical industry profits, but also is not conducive to the reduction of drug prices. Because with the competition of generic drugs, we can reduce the price of the original research drugs, and at the same time, we can also make multinational pharmaceutical companies launch new drugs to China faster. " The president of the pharmaceutical company stressed repeatedly.


How to sell drugs is wrong?


In addition, it is very difficult for pharmaceutical enterprises to sell drugs. In this case, the profits of enterprises cannot be guaranteed, and there is no extra capital to invest in research and development. In the long run, it will be difficult for China's pharmaceutical industry to develop healthily. "Our drug salesmen, the medical representatives, are just like rats when they arrive at the hospital. Everyone is shouting and fighting." Ma manager of an injection manufacturer was particularly helpless when talking about drug sales.


"Drug executives are doing their best when selling drugs," he said Because now even ordinary drug sales will be regarded as commercial bribes, we want to know how to sell them legally. Always give drugs a healthy marketing channel, otherwise it will be difficult for drug companies to survive. "


Ma Jingli told reporters that if it is an over-the-counter drug, enterprises can also spend money on advertising to let consumers know about the drug and purchase the drug, but if it is a prescription drug, they can only let doctors know the efficacy, clinical situation and other information of the drug first, so that medical students can be assured to give patients information.


"We used to train doctors through medical representatives so that doctors could understand a new drug, but now it is also regarded as a commercial bribe. How can we do the sales work in the future?"


It is suggested that drugs can be managed at different levels.

Recommended reading